advanced and metastasized solid malignancies, sorafenib, altered dosing schedule, dose titration, phase I study
Conditions
Interventions
Patients will be treated in exposure escalation cohorts with high-dose sorafenib administered in a weekly pulsatile schedule. Using pharmacokinetic monitoring, the sorafenib dose will be adjusted to a
Sponsors
VU University Medical Center
Eligibility
Inclusion criteria
Inclusion criteria: 1. Histological or cytological documentation of incurable locally advanced or metastatic solid malignancy for which no standard therapy exists. 2. Patients eligible for the expansion cohort must be willing to undergo tumor and skin biopsies, while tumor and skin biopsies are optional for patients enrolled in the escalation cohort. Primary tumor or metastatic site must be accessible for biopsy. Bone metastases are excluded as a biopsy site. 3. Evaluable disease by RECIST version 1.1. criteria 4. Patients must have documented radiographic or clinical progressive disease. 5. Age ¡Ý 18 years. 6. Eastern Cooperative Oncology Group (ECOG) performance status of ¡Ü 1. 7. Normal 12-lead ECG (clinically insignificant abnormalities permitted), and left ventricular ejection fraction (LVEF) > 50% evaluated by multigated acquisition scan (MUGA) or echocardiogram. 8. Normal or regulated thyroid function - supplementation or blocking drugs permitted. 9. Urine analysis: no clinically significant abnormalities. 10. Albumin higher than 25 g/L. 11. Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements to be conducted within 14 days prior to screening: a. Hemoglobin ¡Ý 5,6 mmol/L b. Absolute neutrophil count (ANC) ¡Ý 1,5 x 10*9/l c. Platelet count ¡Ý 100 x 10*9/l d. Total bilirubin ¡Ü 1.5 times the upper limit of normal (ULN). Patients with known Gilbert¡¯s disease who have serum bilirubin ¡Ü 3x ULN may be enrolled. e. ALT and AST ¡Ü 2.5 x ULN (in case of liver metastases: ¡Ü 5 times ULN). f. Serum creatinine ¡Ü 1.5 x ULN or creatinine clearance ¡Ý 50 ml/min (based on MDRD). g. PT-INR/PTT < 1.5 x ULN, unless coumarin derivatives are used. h. Activated partial thromboplastin time < 1.25 x ULN (therapeutic anticoagulation therapy is allowed, if this treatment can be interrupted for a biopsy as judged by the treating physician).
Exclusion criteria
Exclusion criteria: 1. Evidence of a significant uncontrolled concomitant disease, such as cardiovascular disease (including stroke, New York Heart Association Class III or IV cardiac disease or myocardial infarction within 6 months prior to screening, unstable arrhythmia, clinically significant valvular heart disease and unstable angina); nervous system, pulmonary (including obstructive pulmonary disease and history of symptomatic bronchospasm), renal, hepatic, endocrine, or gastrointestinal disorders; or a serious non-healing wound or fracture. 2. Prior radiotherapy in the abdominal or thoracic area or in > 3 vertebrae in the spine (if long interval since previous radiotherapy or radiotherapy in ¡Ü 3 vertebrae, eligibility will be decided on an individual basis by the primary investigator). 3. Poorly controlled hypertension despite adequate blood pressure medication. Blood pressure must be ¡Ü 160/95 mmHg at the time of screening on a stable antihypertensive regimen. Blood pressure must be stable on at least 2 separate measurements. 4. Seizure disorders requiring anticonvulsant therapy. 5. Major surgery, other than diagnostic surgery, within 4 weeks prior to day 1, without complete recovery. 6. Known active bacterial, viral, fungal, mycobacterial, or other infection (including HIV and atypical mycobacterial disease, but excluding fungal infection of the nail beds). 7. Known hypersensitivity to sorafenib or to its excipients. 8. Presence of any significant central nervous system or psychiatric disorder(s) that would interfere with the patient¡¯s compliance. 9. Drug or alcohol abuse. 10. Any evidence of a disease or condition that might affect compliance with the protocol or interpretation of the study results or render the patient at high risk from treatment complications. 11. Unwillingness or inability to comply with study and follow-up procedures. 12. Chemotherapy, radiotherapy, or biologic therapy within the previous 4 weeks; Nitrosoureas or mitomycin C within the previous 6 weeks; Investigational agents within the previous 4 weeks. 13. Clinically significant history of liver disease, including viral or other hepatitis, current alcohol abuse, or cirrhosis. 14. Untreated or active central nervous system (CNS) metastases (progressing or requiring anticonvulsants or corticosteroids for symptomatic control). 15. Patients with a history of treated CNS metastases are eligible, provided that all of the following criteria are met: a. Presence of evaluable or measurable disease outside the CNS b. Radiographic demonstration of stabilization upon completion of CNS-directed therapy and no evidence of interim progression between completion of CNS-directed therapy and the screening radiographic study c. Completion of radiotherapy ¡Ý 8 weeks prior to the screening radiographic study d. Discontinuation of corticosteroids and anticonvulsants ¡Ý 4 weeks prior to the screening radiographic study 16. Pregnant or breast-feeding subjects. Women of childbearing potential must have a negative pregnancy test performed within 7 days of the start of treatment. Both men and women enrolled in this trial must agree to use adequate barrier birth control measures (e.g., cervical cap, condom, or diaphragm) during the course of the trial. Oral birth control methods alone will not be considered adequate on this study, because of the potential pharmacokinetic interaction betwe
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| -To determine the maximum tolerated sorafenib plasma AUC0-12h of high-dose sorafenib when administered in a weekly, pulsatile schedule. -To assess the safety and tolerability of high-dose, pulsatile sorafenib titrated on the target AUC0-12h. | — |
Secondary
| Measure | Time frame |
|---|---|
| Escalation cohorts: -To determine the pharmacokinetic behaviour of sorafenib and its major active metabolite pyridine N-oxide. -To determine a recommended phase II plasma sorafenib AUC0-12h. Expansion cohort: -Preliminary assessment of the efficacy of high-dose, pulsatile sorafenib administered at the maximum tolerated plasma AUC0-12h -To determine the skin and intratumoral concentrations of sorafenib and their correlation with the plasma and whole blood concentrations. -To select 1-2 optimal time points from the AUC0-12h data to determine sorafenib exposure in a high-dose, pulsatile schedule using a finger puncture. | — |
Contacts
Public ContactH.M.W. Verheul
De Boelelaan 1117
Outcome results
None listed